- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Joe Daley, GSW WORLDWIDE
At the end of the day you have tribes, some frequently not on the same "brand" page.
Joe Daley
PRESIDENT | GSW WORLDWIDE/US OPERATIONS
Waste is actually inherent in the very question. We manage investment decisions in silos. Our teams (client/agency team) are traditionally aligned functionally, or by communication channels, or by business segments, or by whatever the niche of the day happens to be. Many clients have functional experts, whether it's PR, medical education, e-marketing, etc. Some clients have strategic marketing separated from tactical marketing (the latter taking the form of marcom-like functions). At the end of the day you have tribes, some frequently not on the same "brand" page. Take the most talented, best marketers, but if you put them in different rooms and ask them as a team to paint a picture of a single apple, the results will not cohere.
Joe Daley
On the top line, waste is created by not leveraging a single brand experience, through fewer tactics, synergistically connected, and strategically driven through channels likely to reach a target audience. ?On the bottom line, it's needless investment in disconnected tactical ideas, and redundancy of functions/people, among other redundancies.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
